Northstar Group Inc. Decreases Position in Johnson & Johnson (NYSE:JNJ)

Northstar Group Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 4.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,971 shares of the company’s stock after selling 1,758 shares during the period. Johnson & Johnson accounts for 1.8% of Northstar Group Inc.’s investment portfolio, making the stock its 11th biggest position. Northstar Group Inc.’s holdings in Johnson & Johnson were worth $4,396,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Virtus ETF Advisers LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $25,000. Krane Funds Advisors LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $26,000. Financial Advantage Inc. bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $28,000. Crewe Advisors LLC boosted its stake in shares of Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares in the last quarter. Finally, Eii Capital Management Inc. bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $39,000. 72.25% of the stock is currently owned by institutional investors and hedge funds.

NYSE JNJ traded up $1.57 during trading hours on Friday, reaching $133.00. 4,856,974 shares of the company’s stock traded hands, compared to its average volume of 7,224,392. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The firm has a market cap of $343.25 billion, a PE ratio of 16.26, a PEG ratio of 2.20 and a beta of 0.69. The firm has a 50-day simple moving average of $130.83 and a 200 day simple moving average of $134.05. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. The company had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. Johnson & Johnson’s revenue was up 1.9% on a year-over-year basis. During the same period last year, the company posted $2.05 EPS. Sell-side analysts forecast that Johnson & Johnson will post 8.65 EPS for the current fiscal year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $0.95 dividend. The ex-dividend date is Monday, November 25th. This represents a $3.80 annualized dividend and a yield of 2.86%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

JNJ has been the subject of a number of recent research reports. Wells Fargo & Co lowered their price target on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, October 16th. Raymond James lowered their price target on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Bank of America reissued a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Finally, Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research report on Friday, October 11th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What is channel trading?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Leave a Reply

Your email address will not be published. Required fields are marked *

*